Validation of a Salivary miRNA Signature of Endometriosis - Interim Data

NEJM Evid. 2023 Jul;2(7):EVIDoa2200282. doi: 10.1056/EVIDoa2200282. Epub 2023 Jun 9.

Abstract

Salivary miRNA Signature of EndometriosisThis interim analysis of the prospective, multicenter, external validation ENDOmiRNA Saliva Test study, confirms the diagnostic performance and reproducibility of the saliva miRNA signature for endometriosis. At a population prevalence of ∼80%, the miRNA signature had a sensitivity of 96.2%, specificity of 95.1%, and area under the curve of 0.96.

Publication types

  • Multicenter Study

MeSH terms

  • Biomarkers, Tumor / genetics
  • Endometriosis* / diagnosis
  • Female
  • Humans
  • MicroRNAs* / genetics
  • Prospective Studies
  • Reproducibility of Results

Substances

  • MicroRNAs
  • Biomarkers, Tumor